|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.190 USD | +4.39% |
|
+16.67% | -66.29% |
| 06-30 | ADC Therapeutics SA Completes Enrollment In LOTIS-7 Phase 1b ZYNLONTA Combination Trial | CI |
| 06-30 | ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bearish | Bearish |
| Resistance | 1.85 | 2.12 | 2.13 |
| Spread/Res. | -35.68% | -43.87% | -44.13% |
| Spread/Supp. | +21.71% | +21.71% | +16.67% |
| Support | 0.9777 | 0.9777 | 1.02 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- ADCT Stock
- Charts ADC Therapeutics SA
Select your edition
All financial news and data tailored to specific country editions
